(Same report may be listed under different category)
Breast cancer
10/15/2017: An effective PARP inhibitor in BRCA-mutated breast cancer
10/1/2017: Preoperative TDM-1 for 12 weeks in HER-2 positive breast cancer achieved significant pathologic complete response
9/23/2017: MONARCH 2: Abemaciclib and fulvestrant combination in breast cancer patients
8/6/2017: Pembrolizumab and chemotherapy as neoadjuvant therapy in breast cancer
7/29/17: Wound complication after breast reconstruction in relation to timing and types of implants following mastectomy
7/22/2017: Dark hair dye and chemical relaxers linked to breast cancer risk
7/15/2017: Olaparib improves progression-free survival in BRCA-associated breast cancer
7/8/2017: Avoid surgery after neoadjuvant therapy for breast cancer
6/18/2017: Adding a second antibody to block HER-2 may lower breast cancer recurrence
5/28/2017: Atezolizumab benefited triple-negative breast cancer patients who obtained objective response
4/30/2017: Ki67 as tool for neoadjuvant chemotherapy decision in ER-positive breast cancer patients (Ellis MJ et al J Clin Onc 2017; 35: 1061-9)
4/23/2017: Predictor of pathological complete response following trastuzumab and lapatinib in early-stage HER2-positive breast cancer (PAMELA)
4/2/2017: Results from MONALLESA-2: Are all CDK4/6 inhibitors equal?
3/18/2017 : Bisphosphate used in adjuvant setting for breast cancer: ASCO guideline
2/25/2017: Results for Veliparib regimen in BRCA+ breast cancer
2/12/2017: Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone
2/11/2017: Novel antibody-drug conjugate targets triple-negative breast cancer
1/29/2017: Extended endocrine therapy for breast cancer
1/21/2017: Radiation-TGF-β inhibition combo elicits activity in metastatic breast cancer
Lung Cancer
11/26/2017: Biomarkers used to predict recurrence and survival after treatment for localized lung cancer
11/19/2017: Anti-inflammatory drug canakinumab may reduce incident lung cancer
11/4/2017: PD-L1 inhibitor，durvalumab, used after chemoradiation for non-small cell lung cancer
10/30/2017: Association of vitamin B supplement and increased lung cancer incidence
9/9/2017: Osimertinib improves outcome of lung cancer patients with EGFR mutation
8/19/2017: Dabrafenib/Trametinib combination approved by FDA for BRAF+ NSCLC
7/2/2017: Atezolizumab improves survival in comparison with docetaxel in previously treated NSCLC
6/11/2017: Modest long-term survival with check-point inhibitors in non-small cell lung cancer
6/3/2017: Japanese phase III Trial of alectinib vs crizotinib in ALK-positive NSCLC
2/5/2017z; NSCLC: Etoposide/cisplatin may be superior to carboplatin/paclitaxel with radiation
1/28/2017: NSCLC assay predicts node status, early recurrence
Colorectal cancer
9/16/2017: Radiation improves outcome in metastatic right-sided colon cancer
9/10/2017: Labetuzumab may provide benefit to relapsed/refractory metastatic colorectal cancer
8/13/2017: Three months adjuvant chemotherapy is not inferior to 6 months in colorecal cancer
6/23/17: Different response and prognosis in right and left colon cancer
2/26/2017: Dual Inhibition proves effective for BRAF-mutated colorectal tumors
Esophageal cancer
12/7/2017: Oral bacterium in association with esophageal cancer
10/8/2017: Impact of neo-adjuant chemotherapy followed by surgical resection on survival in gastric or GEJ cancer with limited metastases
8/26/2017: Perioperative chemotherapy improves survival of gastric and GE junction cancers
3/26/2017: A combo of pembrolizumab and ramucirumab is active for advanced gastric and GE junction cancer
2/4/2017: Breathing test may diagnose esophageal and gastric cancer
Gastric cancer
10/8/2017: Impact of neo-adjuant chemotherapy followed by surgical resection on survival in gastric or GEJ cancer with limited metastases
8/26/2017: Perioperative chemotherapy improves survival of gastric and GE junction cancers
3/26/2017: A combo of pembrolizumab and ramucirumab is active for advanced gastric and GE junction cancer
Pancreatic cancer
12/2/2017: Eryaspase plus chemotherapy benefits metastatic pancreatic cancer
11/12/2017: Germline mutations in sporadic pancreatic cancer patients
7/9/2017: Hydroxychloroquine enhances antitumor activity of neoadjuvant chemotherapy in pancreatic cancer
6/17/2017: Stress granules in pancreatic cancer and drug resistance
6/10/2017: Prognostic value of plasma circulating DNA in pancreatic cancer patient
5/20/2017: Newfound signal helps pancreatic cancer cells hide from immune system
4/16/2017: ASCO Updates Potentially Curable Pancreatic Cancer Guideline
4/8/2017: Chemoimmunotherapy regimen safe and active in pancreatic cancer
1/22/17: Vantictumab combination benefits stage 4 pancreatic cancer
1/14/2017: Addition of capecitabine to adjuvant chemotherapy extends survival in pancreatic cancer
Hepatocellular carcinoma
9/17/2017: Nivolumab is active in advanced hepatocellular carcinoma
Biliary tract cancer
6/4/2017: Adjuvant capecitabine for biliary tract cancer improves overall survival
Ovarian cancer
10/7/2017: Retroperitoneal exploration improves survival in optimally debulked ovarian cancer
3/11/2017: Trial of Quisinostat in ovarian cancer meets primary endpoints
Cervical cancer
4/22/2017: Early phase report of combination treatment with HPV vaccine and chemotherapy in advanced cervical cancer
Bladder cancer
11/25/2017: Experimental “nano-chemo” particle to treat bladder cancer
3/5/2017: Pembrolizumab vs chemotherapy in second-line treatment of advanced urothelial carcinoma
Prostate cancer
11/18/2017: Abiraterone or docetaxel: which is optimal of hormone-sensitive high-risk prostate cancer?
8/12/2017: Two trials demonstrated early Abiraterone intervention benefited prostate cancer
5/6/2017: A Multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer
2/18/2017: Padeliporfin vascular-targeted photodynamic therapy for low grade prostate cancer
1/15/2017: Urine gene expression assay may improve the diagnosis of high-grade prostate cancer
Kidney Cancer
12/16/2017: Nivolumab plus Ipilimumab vs Sunitinib alone as first-line therapy for metastatic renal cell carcinoma
5/21/2017: Is Cabozantinib a standard of care for advanced renal cell cancer?
4/29/2017: Inhibiting histone deacetylase to reverse resistance to angiogenesis inhibitors
3/4/2017: First look at combo with immunotherapy in untreated metastatic renal cell carcinoma
Head & Neck Cancer
8/20/2017: Plasmid EBV DNA screening for nasopharyngeal cancer
Srcoma
9/3/2017: Aldoxorubicin improves outcome in relapsed/refractory sarcoma
Melanoma
11/5/2017: Adjuvant combination therapy for stage III BRAF-mutant melanoma doubles relapse-free survival
10/14/2017: Effect of Nivolumab versus Ipilimumab in resected stage III or IV melanoma
9/2/2017: Combination therapy effective in melanoma patients with brain metastases
8/5/2017: Intratumoral injection of plasmid/lymphokine-12 enhances melanoma response to pembrolizumab
Malignant pleural mesothelioma
1/7/2017: Arginine deprivation shows promise for malignant pleural mesothelioma
Neuroendocrine tumor
9/30/2017: 177-Lu-Dotate therapy for neuroendocrine tumors
Lymphoma
12/17/2017: Yescarta benefited refractory lymphoma patients 7/30/2017: Clinical trial shows persistent complete response in recurrent/refractory diffuse large B-cell lymphoma
5/14/2017: Non-engineered T cell therapy produces durable responses in hematologic malignancies
4/15/2017: Final Results of European Intergroup Trial of Early PET-Adapted Treatment in Hodgkin Lymphoma
4/1/2017: Brentuximab vedotin beats standard of care for cutaneous T-cell lymphoma
2/19/2017 : KTE-C19 shows impressive responses in aggressive lymphomas
Myeloma Amyloidosis
2017/12/23: New promising treatment for refractory myeloma: CAR-T therapy
11/11/2017: Amyloidosis
5/14/2017: Non-engineered T cell therapy produces durable responses in hematologic malignancies
3/12/2017: Anit-BCMA CAR-T-cell therapy approaches 80% response rate in multiple myeloma
Side-effects:
12/10/2017: Using tocilizumab to manage adverse effects from anti-PD-1 drugs
4/9/2017: Immunotherapy may hasten tumor growth in some patients
3/25/2017: Rare complications of checkpoint inhibitors to the heart
1/1/2017: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer
Diagnosis
12/3/2017: FDA granted market approval for FoundationOne’ NGS in vitro diagnostic test
11/26/2017: Biomarkers used to predict recurrence and survival after treatment for localized lung cancer
5/27/2017: New imaging method may predict immunotherapy response early
2/4/2017: Breathing test may diagnose esophageal and gastric cancer
1/28/2017: NSCLC assay predicts node status, early recurrence
1/15/2017: Urine gene expression assay may improve the diagnosis of high-grade prostate cancer
Novel therapeutic approach:
12/24/2017: Combination of Alisertin, an aurora kinase A inhibitor and TAK-228 in solid tumors
12/2/2017: Eryaspase plus chemotherapy benefits metastatic pancreatic cancer
11/25/2017: Experimental “nano-chemo” particle to treat bladder cancer
10/21/2017: Luspatercept in treatment of lower-risk myelodysplastic syndrome
8/5/2017: Intratumoral injection of plasmid/lymphokine-12 enhances melanoma response to pembrolizumab
7/16/2017: Novel tropomyosin receptor kinase inhibitor produces unexpected response across different tumor types
5/20/2017: Newfound signal helps pancreatic cancer cells hide from immune system
5/14/2017: Non-engineered T cell therapy produces durable responses in hematologic malignancies
4/29/2017: Inhibiting histone deacetylase to reverse resistance to angiogenesis inhibitors
3/12/2017: Anti-BCMA CAR-T-cell therapy approaches 80% response rate in multiple myeloma
2/18/2017: Padeliporfin vascular-targeted photodynamic therapy for low grade prostate cancer
2/11/2017: Novel antibody-drug conjugate targets triple-negative breast cancer
1/22/17: Vantictumab combination benefits stage 4 pancreatic cancer
1/21/2017: Radiation-TGF-β inhibition combo elicits activity in metastatic breast cancer
1/7/2017: Arginine deprivation shows promise for malignant pleural mesothelioma
Epidemiology
12/30/2017: Microbiome on tumor development and immunotherapy effect
12/7/2017: Oral bacterium in association with esophageal cancer
10/30/2017: Association of vitamin B supplement and increased lung cancer incidence
9/24/2017: Circadian rhythm disruption linked to cancer risk
7/23/2017: Statin criteria may help to identify high-risk cancer group
7/22/2017: Dark hair dye and chemical relaxers linked to breast cancer risk
5/13/2017: Heme iron and nitrate additives implicated early death in population-based study
5/7/2017: Gut bacteria may enhance, or hamper, response to anti-PD-1 agents
1/8/2017: Cancer death in America continues to drop
Prevention